Precigen, Inc.

PGEN

$240M

Micro Cap

NASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaGERMANTOWN143 employees

Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 26, 2026

18d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

1 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date PRGN-3005 (priority)

2/26/2026

For advanced or refractory solid tumors. BLA filing. Extracted from SEC filing: 8-K

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

PRGN-2009 plus Pembrolizumab

Phase 2

Cervical Cancer

PRGN-2012 - Phase I; Dose Level 1

Phase 2

Recurrent Respiratory Papillomatosis

Drug Name	Phase	Indication	Designations
PRGN-2009 plus Pembrolizumab	Phase 2	Cervical Cancer	-
PRGN-2012 - Phase I; Dose Level 1	Phase 2	Recurrent Respiratory Papillomatosis	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

PGEN News